This educational initiative is targeted to neuro-oncologists, pediatric neuro-oncologists, neurosurgeons, neuroradiologists, medical oncologists, neurologists, neuro-oncology researchers, and other members of the neuro-oncology team who care for patients with neurofibromatosis type 1 (NF1). Designed and developed to provide an exhaustive overview of novel and emerging data, as well as establish a foundational context of NF1 disease state complexity, this activity will begin by identifying keystone diagnostic signs, symptoms, and clinical hallmarks in pediatric patients, and describe the genetic etiologies and multi-system pathophysiologies that have historically made NF1-associated plexiform neurofibromas so difficult to treat. Attendees will then gain insights from expert faculty regarding the pivotal shortcomings of traditional treatment approaches and the new horizons that have accompanied the burgeoning emergence of novel pharmacologic therapies, most notably MEK inhibitors. Finally, top-level clinical experts will guide attendees through a case-based section that explores the vital role of the neuro-oncology clinician and researcher in the evolving NF1 management paradigm, and provides activity participants an opportunity to design evidence-based treatment regimens for symptomatic, inoperable NF1-related tumors.
This educational initiative is targeted to neuro-oncologists, pediatric neuro-oncologists, neurosurgeons, neuroradiologists, medical oncologists, neurologists, neuro-oncology researchers, and other members of the interprofessional, multi-disciplinary neuro-oncology team.
Welcome and Introductions/Pre-test, Jaishri Blakeley, MD
Embracing Complexity: The Etiology, Pathophysiology, and Clinical Manifestations of Neurofibromatosis Type 1, Bruce R. Korf, MD, PhD (Activity Chair)
Navigating Novelty in Plexiform Neurofibroma Management: An Exploration of Emerging Data and Adaptive Strategies, Andrea M. Gross, MD
Bridging Chasms in NF1: The Pivotal Placement of the Neuro-Oncology Team in the New Paradigm, Jaishri Blakeley, MD
Conversation with the Experts: Audience Q&A/Post-test, Faculty Panel Moderated by Bruce R. Korf, MD, PhD
At the conclusion of this live internet activity, participants will gain the skills and/or knowledge to:
- Identify the keystone diagnostic symptomatology and clinical hallmarks of neurofibromatosis type 1 (NF1), especially in the pediatric patient population.
- Describe the genetic origins and the complex, multi-system pathophysiology of NF1, with an emphasis on the clinical gravity and historical intractability of plexiform neurofibromas.
- Review traditional approaches for treating plexiform neurofibromas in patients with NF1, including surgery, radiation, and surveillance, and highlight the crucial clinical chasms that remain.
- Examine emerging pharmacologic therapies for managing symptomatic, inoperable plexiform neurofibromas, including an appraisal of completed and ongoing clinical trials and recent FDA approvals, with a focus on MEK inhibition.
- Evaluate the role of the neuro-oncology clinician and researcher in developing and delivering novel, cutting-edge NF1 therapeutic approaches and galvanizing ongoing renewal of the treatment calculus.
- Using a case-based format, design evidence-based management strategies for clinically significant, non-surgical, NF1-associated plexiform neurofibromas and low-grade gliomas.
Bruce R. Korf, MD, PhD
Associate Dean for Genomic Medicine
School of Medicine
Wayne H. And Sara Crews Finley Endowed Chair in Medical Genetics
University of Alabama at Birmingham (UAB)
Chief Genomics Officer, UAB Medicine
Jaishri Blakeley, MD
Director, The Johns Hopkins Comprehensive Neurofibromatosis Center
Professor of Neurology, Neurosurgery, and Oncology
The Johns Hopkins University
Andrea M. Gross, MD
Assistant Research Physician, Pediatric Oncology Branch
National Institutes of Health, Center for Cancer Research
Fee Statement: There is no fee to participate in this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a post-test and evaluation, statements of credit for physicians will be issued within 30 business days.
The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.
Pre-Recorded Session with Credits available - Now Available! On-demand Webcast: Neuro-Oncology Perspectives in Neurofibromatosis Type 1
Did you miss the CME-accredited webinar, Neuro-Oncology Perspectives in Type 1: New Horizons in the Era of MEK Inhibition, that was originally presented live on Thursday, December 3rd? The on-demand webcast is now available for viewing at https://www.ceconcepts.com/ondemand-SNO. To receive 1.5 hours of CME credit, you will need to complete the pre-test, view the webcast, and complete the post-test and evaluation.
Any questions can be directed to Creative Educational Concepts (CEC Oncology) at firstname.lastname@example.org.